Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON49080
NL-OMON49080
Suspended
Phase 3

COVID-19: addition of azithromycin to chloroquine treatment - CO VOR IT

Erasmus MC, Universitair Medisch Centrum Rotterdam0 sites60 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsCOVID-19 infection10024970

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
COVID-19 infection
Sponsor
Erasmus MC, Universitair Medisch Centrum Rotterdam
Enrollment
60
Status
Suspended
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Proven diagnosis of COVID\-19 by positive PCR in any specimen \< 48 hours
  • •prior to randomization.
  • •Age \>\= 18 year
  • •Hospitalized patients with illness of any duration, and SpO2 \<\= 94% on room

Exclusion Criteria

  • •Severe hypoxemic respiratory failure expected to die \< 72 hours after
  • •ICU admission \< 72 hours
  • •Allergy for chloroquine or azithromycin
  • •Pregnancy
  • •QT\-prolongation: pre\-existent: QTc males \>450ms, QTc females \> 470ms at
  • •day 1 and at day 2
  • •Myasthenia gravis

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
COVID-19: addition of azithromycin to chloroquine treatmentCOVID-19Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
EUCTR2020-001527-14-NLErasmus MC60
Active, not recruiting
Phase 1
Azithromycin added to Hydrochloroquine in Patients Admitted to Intensive Care due to Coronavirus Disease 2019 (COVID-19) - Randomised Controlled Trial, phase III
EUCTR2020-001456-18-CZadacní fond Donatio intensivistam240
Not yet recruiting
Phase 3
Efficay of two hydroxychloroquine based drug combination regimens in comparison to standard of care in The Treatment of Hospitalized COVID-19 PatientsCOVID 19
PACTR202010519682638ational Institute for Pharmaceutical Research and Development NIPRD210
Completed
Not Applicable
Anti Infective Agents Impact in COVID-19 PneumoniaCOVIDPneumonia, Viral
NCT04453501Centre d'Investigation Clinique et Technologique 805132
Completed
Phase 2
Azithromycin Plus Chloroquine Versus Atovaquone-Proguanil For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In South AmericaMalaria, Falciparum
NCT00084227Pfizer244